

MC Partners Inc.

*Suite 300 – 576 Seymour Street
Vancouver, BC V6B 3K1
Tel: (604) 688-6775
Fax: (604) 688-6995*

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

MC PARTNERS INC. ANNOUNCES PROPOSED QUALIFYING TRANSACTION

October 17, 2012

**TSX Venture Exchange
Trading Symbol: MCT.P**

Vancouver, British Columbia – MC Partners Inc. (“MCP” or the “Company”), a capital pool company listed on the TSX Venture Exchange (the “Exchange”), is pleased to announce that it has reached an agreement in principle (the “Agreement”) to acquire all of the issued and outstanding shares of bioMmune Technologies Inc. (“BIO”). Under the terms of the Agreement, the Company will issue to the shareholders of BIO a total of 5,000,000 shares of the Company at a price of \$0.15 per share, to be issued at the closing.

The Agreement is subject to Exchange approval and will constitute the Company’s qualifying transaction (the “QT”) for the purposes of the CPC policies of the Exchange. On conclusion of the proposed QT, MCP will change its name to reflect the nature and character of the business of BIO, with the resulting issuer trading as a Tier 2 Research and Development Issuer on the Exchange. Subject to the discretion of the Exchange, the proposed QT does not constitute a Non-Arms’ Length Transaction under the Policies of the Exchange.

BIO is a private British Columbia company that was formed to commercially exploit a number of patents and patent applications that surround three technologies.

The first technology involves the discovery of HDACi’s (Histone Deacetylase) which are proteins (enzymes) important for the regulation of cell growth and have been found to be novel drugs for the treatment of cancers. BIO plans to discover new HDACi inhibitors, which will be active and recognize cancer cells and results in the body’s immune system being able to kill the cancer cells.

The second technology deals with Calcium Channels which are a multi member family with over 10 different proteins. These channels activities are regulated and regulate the concentration of calcium (Ca) in different places in cells and regulates the concentration of Ca which is very important for the activity of cells involved in the immune system. This channel, designed as Cav 1.4, is important and identifying new calcium channel regulators (blockers) will be important to improve the activity of the immune system to combat cancers, infections and also autoimmunities.

The third technology is called CD74 which is a protein involved in the immune system and its regulation. Finding ways or compounds that regulate its activity will improve the immune system to combat infections, cancers and autoimmune diseases.

The closing of this transaction is subject to a number of conditions, including: (i) the execution of a definitive agreement; (ii) completion of successful due diligence by the parties, (iii) the Company successfully completing a financing for gross proceeds of a sufficient amount to fund the business plan and to meet the minimum listing requirements of the Exchange, (iv) Exchange approval and (v) shareholder approval, if required.

The Company intends to complete a private placement of 10,000,000 units of MCP at a price of \$0.15 per unit for gross proceeds of \$1,500,000 (the "Financing"). Each unit will consist of one common share of the Company and one common share purchase warrant of the Company (the "Warrant"). Each whole Warrant will entitle the holder to purchase one additional common share of the Company at a price of \$0.25 for a period of 12 months from the completion of the Financing

Sponsorship of a Qualifying Transaction of a capital pool company is required by the Exchange unless exempt in accordance with Exchange policies. The Company intends to retain a qualified sponsor as soon as is reasonably practicable following the date hereof to act as its sponsor in connection with the QT in accordance with TSX Venture Exchange Policy 2.2.

Trading in the common shares of the Company remains halted in connection with the dissemination of this News Release and will recommence at such time as the Exchange may determine, based on the satisfaction of certain requirements pursuant to TSX Venture Exchange Policy 2.4.

Further details of the proposed transaction will follow in future news releases once the particulars of the QT are finalized. Prior to the resumption of trading of the Company, further details of the proposed transaction, including the financial position and shareholders of BIO will be provided.

On behalf of the Board of Directors

"John Morgan"

John Morgan
Chief Executive Officer

For further information please contact:

John Morgan
Telephone: (604) 614-1385

The information in this news release regarding BIO and its management has been provided to the Company by BIO and has not been independently verified by the Company.

Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange Requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties, including, without limitation, the risk that: (a) the transaction may not be completed for any reason whatsoever, (b) the business of the resulting may differ from the intended business stated in this news release, (c) the Company may not be able to complete the Financing as stated or at all, (d) the cash and cash equivalents of the Company and the Net Tangible Assets of the Company may be less than expected on closing, (e) the Exchange may not approve the transaction or any of the other transactions contemplated under the Agreement and (g) if shareholder approval is required, the shareholders may not approve the transaction or any of the transactions contemplated under the Agreement. Because of these risks and uncertainties and as a result of a variety of factors, the actual results,

expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Although the Company and BIO believe that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company and BIO disclaim any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.